Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01309568 · ClinicalTrials.gov registry record
"Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"
A clinical trial, sponsored by Quidel Corporation.
- Completed
- Registry status
- 2,500
- Enrollment target
NCT01309568: Completed study, sponsored by Quidel Corporation.
NCT01309568 is a clinical trial that has completed, run by Quidel Corporation. The registered enrollment target is 2,500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01309568 has completed, sponsored by Quidel Corporation.
- COMPLETED
- Registry status
- 2,500 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate the clinical performance of the Quidel Reader Influenza A+B test and Quidel Reader with the following sample types: nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash. Clinical performance will be based on comparison of Quidel Reader Influenza A+B results to cell culture at a Central Reference or Alternative Laboratory.
Primary Outcome
Accurate diagnosis of infection with influenza A or influenza B confirmed by culture
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-04 |
What the finished NCT01309568 record still lists
NCT01309568 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01309568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01309568 about?
NCT01309568 is a clinical study titled ""Quidel Reader Influenza A + B Test 510(k) and CLIA Waiver Field Study"". The objective of this study is to demonstrate the clinical performance of the Quidel Reader Influenza A+B test and Quidel Reader with the following sample types: nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash. Clinical performance will be based on comparison of Quidel Reader Influ...
What is the current status of trial NCT01309568?
This trial is currently completed. The enrollment target is 2,500 participants. The study started on 2011-02. Estimated completion is 2011-04.
Who is sponsoring clinical trial NCT01309568?
This trial is sponsored by Quidel Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia